Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temanogrel PK/PD and Safety with Aspirin/Clopidogrel
NCT02419820Phase 1Terminated
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Mar 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of temanogrel in acute coronary syndrome (ACS) (16 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Maximum Plasma Concentration at Day 7, Time to Maximum Plasma Concentration at Day 7 and 3 more. Started Mar 2015; status: terminated.
02
Drugs
temanogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02419820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419820.